Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA-1 peptide vaccination after allogeneic stem cell transplantation
ISRCTN80896844Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2008
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of HA-1 peptide vaccine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 4 more (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Toxicity and Appearance of HA-1-specific CD8+ lymphocytes. Started Dec 2008; status: completed.
02
Drugs
HA-1 peptide vaccine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN80896844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN80896844.